SpectrumX Holdings UK Ltd, a UK-based healthcare and pharmaceutical company, has strengthened its senior management team with two appointments.
Dr Donna Lockhart is joining as head of medicines consultant and Greg Whelan has been appointed as group sales director.
These newly created roles will support the company’s growth as it progresses towards clinical trials and the commercial launch of its non-pharmaceutical products, SpectrumX said.
Dr Lockhart brings more than 30 years’ experience in the pharmaceutical industry, including having been medical director at Pfizer and global director of regulatory and medical affairs at Reckitt Benckiser. In the role of head of medicines, Lockhart will be responsible for SpectrumX’s clinical programmes, including directing the SPC-069 clinical trial, which is due to commence in the coming months.
Whelan’s career in the healthcare sector spans more than 20 years with senior sales positions at blue-chip organisations such as GlaxoSmithKline, MSD and Omnicell.
Whelan will be responsible for leading sales strategy and supporting sales delivery for the company’s Spectricept line of sanitisers – a product range aimed at hospitals and health facilities, businesses and retailers – and, following the receipt of regulatory approval in due course, its pharmaceutical products.
“With our upcoming pharmaceutical clinical trials and launch of our non-pharmaceutical products, the addition of Donna and Greg will be of great value to SpectrumX. Donna’s proven expertise in clinical drug development will be instrumental in ensuring that we are best positioned for success while Greg has an impressive record of aggressively growing sales,” said Damien Hancox, the chief executive officer and co-founder of SpectrumX.